MediRox at Equalis’ annual meeting
With thanks to their efforts – and for MediRox fantastic Owrens PT of course – the national variation for patients PT INR is less than 5%, nationally, compared to a variation of 20-30 per cent shown in European and American studies.
The annual meeting is a combination of an exhibition and lectures given by several opinion leaders in haemostasis. This year had a focus on PT INR, D-dimer and an update on NOAC situation in the lab. Luckily we could notice in the stat reports that MediRox is increasing in sales and is still a leading supplier of PT INR, D-dimer and controls in Sweden.